Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell …
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints, event-free survival (EFS), as a perioperative treatment regimen for patients with…#merck #mrk #msd #keytruda #iiia #nsclc #efs #fda #eliavbarr #keynote867 (Source: Reuters: Health)
Source: Reuters: Health - March 1, 2023 Category: Consumer Health News Source Type: news
Alembic Pharma gets USFDA nod to market generic cancer drug
Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2023 Category: Pharmaceuticals Source Type: news
PET AI model improves lung cancer staging
An artificial intelligence (AI) model based on routine data from F-18 FDG-PET/C...Read more on AuntMinnie.comRelated Reading:
PET/CT radiomics could help select patients for immunotherapy
Can CT radiomics predict NSCLC immunotherapy response?
PET/CT improves survival in lung cancer patients
CT lung cancer screening saved more than 10K lives
PET tracer proves effective for assessing immunotherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 27, 2023 Category: Radiology Source Type: news
Top Questions When Treating Resectable NSCLC Top Questions When Treating Resectable NSCLC
Dr Mark Kris discusses topics of interest and insights that emerged from a meeting of thoracic oncology practitioners.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2023 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Preoperative Immunochemotherapy for Locally Advanced NSCLC Preoperative Immunochemotherapy for Locally Advanced NSCLC
A new study evaluates the efficacy of neoadjuvant immunochemotherapy for locally advanced NSCLC in a real-world setting. What is the optimal treatment cycle?Translational Lung Cancer Research (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 21, 2023 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news
Immunotherapy With Radiotherapy and Stage IV NSCLC Prognosis Immunotherapy With Radiotherapy and Stage IV NSCLC Prognosis
These findings suggest that stage IV NSCLC patients who receive radiotherapy in addition to immunotherapy may not realize significant improvements in prognosis.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 16, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
WEDNESDAY, Feb. 15, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is associated with positive five-year outcomes, according to a study published online Feb. 15 in Clinical Cancer Research.
Samuel... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2023 Category: Pharmaceuticals Source Type: news
Favorable Long-Term Outcomes for Operable NSCLC After Neoadjuvant Immunotherapy
(MedPage Today) -- Patients with operable non-small cell lung cancer (NSCLC) had a 5-year overall survival (OS) rate of 80% and a recurrence-free survival (RFS) rate of 60% following neoadjuvant immunotherapy with nivolumab (Opdivo), data from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2023 Category: Hematology Source Type: news
Survival Gains, Savings With Next-Generation Sequencing in NSCLC Survival Gains, Savings With Next-Generation Sequencing in NSCLC
The modeling study shows"clinically meaningful" gains in survival and lower costs with NGS over single-gene testing in metastatic nonsquamous NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Predicting Survival to Chemo and Chemoimmunotherapy in NSCLC Predicting Survival to Chemo and Chemoimmunotherapy in NSCLC
Better understanding the predictive factors of immunotherapy and chemoimmunotherapy efficacy could help guide treatment decisions in NSCLC.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Sublobar Resection Not Inferior to Lobar Resection for T1aN0 NSCLC
THURSDAY, Feb. 9, 2023 -- Sublobar resection is not inferior to lobar resection for patients with peripheral non-small cell lung cancer (NSCLC) with a tumor size of 2 cm or less, according to a study published in the Feb. 9 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 9, 2023 Category: Pharmaceuticals Source Type: news
Severe, Atypical Skin Reactions With Amivantamab in NSCLC Severe, Atypical Skin Reactions With Amivantamab in NSCLC
Some of the cutaneous adverse events to amivantamab, which targets both EGFR and MET, can be severe and have atypical presentations, which led to dose reductions in five of six cases.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Less Invasive NSCLC Surgery Does Not Compromise Survival Less Invasive NSCLC Surgery Does Not Compromise Survival
A US trial showing that sublobar resection achieves similar survival outcomes as lobar resection could usher in precision lung cancer surgery, says expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
NSCLC Survival Improved With FDG PET/CT Imaging Before Radiation Therapy
FRIDAY, Feb. 3, 2023 -- Almost half of patients with non-small cell lung cancer (NSCLC) are not being imaged in accordance with national guidelines prior to subsequent radiation therapy, according to a study recently published in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
